Valeritas Holdings, Inc. announced the publication of study results reflecting real-world clinical practice showing that nursing home residents with type 2 diabetes who used the V-Go® Insulin Delivery device had improved glycemic control compared to residents who received insulin via traditional injections with syringes or pens. Use of V-Go was also associated with reduced nursing staff time and labor costs for insulin administration. The study was published in the January 2017 print issue of the Journal of Gerontological Nursing (43(1): 10-16). The study was a retrospective chart review of patients with type 2 diabetes who resided in a single nursing home and who were receiving basal and bolus insulin via syringes or pens (standard of care or SOC) to manage blood glucose levels. Patients were included in the V-Go group if they had used V-Go during a six-month timeframe. V-Go patients were matched to SOC patients based on their mean 30-day blood glucose (BG) measures at baseline. The primary endpoint was the proportion of BG time in the range of 100 mg/dL to 200 mg/dL, which reflected the target glycemic range of older adults with complex health status. Secondary endpoints included mean daily BG measurements, glycemic fluctuations and excursions and the number of daily injection sites.